In Brazil, since there are no current recommendations for prostate cancer screening according to health policies, 54.4% of all diagnoses occur in advanced stages, which might skyrocket the requirement for androgen receptor pathway inhibitors in the coming years.(31). This evidence concerns the gene AR and prostate carcinoma.